cis-Diamminedichloroplatinum: a cytostatic with an ototoxic effect.
Among 74 patients treated with cis-diamminedichloroplatinum in total doses of 130-590 mg/m2 body surface area, high tone hearing loss was observed in 3. The caloric and rotatory responses were reduced in 3 other patients. Optokinetic responses remained normal in all patients.
D000293:Adolescent; D000328:Adult; D002945:Cisplatin / Q000009:adverse effects* / Q000633:toxicity; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D034381:Hearing Loss / Q000139:chemically induced*; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D013736:Testicular Neoplasms / Q000188:drug therapy; D014012:Tinnitus / Q000139:chemically induced*
D002945:Cisplatin